Navigation Links
Aethlon Medical Announces Washington, DC Shareholder Presentation
Date:12/20/2010

ral load reduction at the outset of standard of care drug regimens.  
  • Human Immunodeficiency Virus (HIV):  Provides a potential therapeutic option for HIV-infected individuals to manage disease progression once they become resistant to antiviral drug regimens.
  • Bioterror and Pandemic Threats:  Represents the most advanced broad-spectrum strategy to address untreatable bioterror and emerging pandemic threats.

  • The Hemopurifier® is an expansive multi-patented platform technology whose mechanism of action can be leveraged to provide therapeutic, diagnostic, and biomarker discovery solutions. As a therapeutic, the Hemopurifier® is a single-use disposable cartridge designed for implementation within the established infrastructure of dialysis machines and other blood circulatory pumps already located in hospitals and clinics worldwide.

    In design, our Hemopurifier® is a selective filtration device containing affinity agents that tightly bind to high-mannose structures unique to the surface of exosomes produced by cancer and glycoproteins residing on the envelope of viruses. These agents are immobilized around approximately 2800 porous hollow fibers that run the interior length of our device. The resulting design provides us the novel ability to separate both exosome and viral targets away from blood cells so they can then be selectively and permanently removed from the circulatory system. In application, blood circulation is established into the Hemopurifier® via a catheter or other blood access device. Once blood flow has been established, treatment benefit is immediate as the entire circulatory system can pass through the Hemopurifier® in as little as 15 minutes.

    Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the development of exosome-targeted products and services that improve cancer diagnosis, provide post-treatment cancer surveillance, and aid in the discove
    '/>"/>

    SOURCE Aethlon Medical, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
    2. Aethlon Medical to Present at LD MICRO Conference on December 3, 2009
    3. Aethlon Medical, Inc. Announces Annual Meeting Results
    4. Aethlon Medical Announces Data Supported Strategy to Increase Hepatitis-C (HCV) Cure Rates
    5. Halt Medical Presents Strong Results of International Fibroid Studies at National Institutes of Health Global Congress
    6. Medical science helps UK athletes reach peak performance
    7. Rush-Copley Medical Center Selects Pharmacy Xpert from Thomson Reuters to Improve Medication Management
    8. Cephalon Announces Chairman and CEO to Remain on Medical Leave of Absence Indefinitely
    9. Integrated Medical Systems Technology Recognized as Qualified Therapeutic Discovery
    10. Wound Management Technologies to Present at LifeTech Capital Miami Medical Investors Conference
    11. Cardium to Present at the LifeTech Capital Miami Medical Investors Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/23/2014)... 2014 New spin-out from ... Cambridge Innovation Capital and Johnson & Johnson Development ... company focused on harnessing the potential of circulating ... and treatment, today announced it has raised £4m ... and including Cambridge Innovation Capital and Johnson & ...
    (Date:9/22/2014)... developed by researchers at the USC Viterbi School ... a 3-D microfluidic system quickly and cheaply by ... , Microfluidic systems are used in many fields ... small volumes of fluids for use in applications ... clinical diagnostic testing, and synthetic chemistry. Traditionally, microfluidic ...
    (Date:9/22/2014)... discovered a way to create a highly sensitive chemical ... The imperfections have unique electronic properties that the researchers ... gas molecules by 300 times. , The study is ... Communications . , Amin Salehi- Khojin, asst professor of ... Asadi, graduate student and Bijandra Kumar, post doc where ...
    (Date:9/22/2014)... California (PRWEB) September 22, 2014 ... and chitosan are natural biopolymers available in abundance ... from easily available resources such as shells of ... chitosan is mainly due to the high percentage ... Chitosan finds application in various industries owing to ...
    Breaking Biology Technology:Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 2Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 3Inivata Raises £4m to Realise the Potential of ctDNA Analysis to Improve Cancer Treatment Through Simple Blood Tests 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5Graphene imperfections key to creating hypersensitive 'electronic nose' 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 2Emergence of New Application Areas to Drive the Global Chitin and Chitosan Market, According to New Report by Global Industry Analysts, Inc. 3
    ... successful debut at the Medical Design & Manufacturing East Show. , ... ... of Zeus, Inc., made a successful debut at the Medical Design & ... Convention Center in New York. , , ,"The MD&M East show ...
    ... has published a white paper titled “Avanta ... Advanced Ceramic Nanopowders” online. This white paper ... powders on a nanometer scale, as well ... of products. Advanced ceramic nanopowders are critical ...
    ... The U.S. Food and Drug,Administration (FDA) ... to recommend the approval of tolvaptan, Otsuka ... patients with hyponatremia., "Otsuka is pleased ... approval of tolvaptan, an investigational selective,V2-vasopressin receptor ...
    Cached Biology Technology:Polymathic Analytical Labs Debuts at World's Largest Medical Design & Manufacturing Exhibition 2 SACHEM Launches New Products for High Purity Advanced Ceramic Powders : Avanta AC™ Advanced Ceramics Solutions Offer Unique Advantages over Inorganic Bases in the Manufacture of Advanced Ceramic Nanoparticles 2U.S. Food and Drug Administration Advisory Committee Recommends Approval of Tolvaptan, an Investigational Treatment for Hyponatremia 2
    (Date:9/23/2014)... could be as good for your mental as your ... by the University of Warwick,s Medical School using data ... BMJ Open focused on mental wellbeing and ... associated with an individual,s fruit and vegetable consumption. , ... or more portions of fruit and vegetables a day, ...
    (Date:9/23/2014)... welfare consequences of removing infant chimpanzees from their mothers ... impacts of this type of early life experience. In ... 60 chimpanzees and concluded that those who were removed ... humans as pets or performers are likely to show ... research project, published today in the open-access journal ...
    (Date:9/22/2014)... --- Many native species have vanished from tropical ... Florida scientists have discovered how fossils can be ... key lies in organic materials found in fossil ... functioned, according to a new study available online ... Journal of Herpetology . Pre-human island ecosystems provide ...
    Breaking Biology News(10 mins):Eating five a day may keep the blues away 2Chimpanzees raised as pets or performers suffer long-term effects on their behavior 2Answer to restoring lost island biodiversity found in fossils 2
    ... Mental disorders, such as depression, anxiety disorders, addiction ... care systems around the world. In the EU alone, ... this corresponds to 83 Million citizens suffer from ... in the EU as the most disabling disorder of ...
    ... researchers at The Medical College of Wisconsin, in Milwaukee, ... how a synthetic chemical mimics abscisic acid (ABA), a ... environmental conditions such as drought. The results are published ... in advance of print publication later. For years scientists ...
    ... twin awards from the National Science Foundation (NSF) totaling ... Computational Sciences (NICS) will add 300 teraflops to the ... have access to more than 200 million additional service ... available from NICS to over 800 million and benefitting ...
    Cached Biology News:23rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 223rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 323rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 423rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 523rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 623rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 723rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 823rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 923rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 1023rd ECNP Congress: Pioneering CNS research -- translating neuroscience into clinical progress 11Growing drought-tolerant crops inching forward 2NICS to add more than 300 Teraflops to the NSF’s computing capacity 2
    Mouse polyclonal antibody raised against a partial recombinant CD320. NCBI Entrez Gene ID = 51293...
    Mouse monoclonal antibody raised against a partial recombinant TTC3. NCBI Entrez Gene ID = TTC3...
    ... antibody raised against a partial ... Immunogen: TOPORS (NP_005793, 98 ... recombinant protein with GST tag. ... NM_005802 ...
    Mouse monoclonal antibody raised against a partial recombinant PASK. NCBI Entrez Gene ID = PASK...
    Biology Products: